This post will include links to articles about the treatment of tumors that have developed resistance to a targeted therapy.
Disease Flare
This post is for links to articles about disease flare (the rapid increase in cancerous growth after a kinase inhibitor is discontinued).
Posted in Uncategorized
1 Comment
ALK Antibodies
This post covers potential ALK Antibody treatments.
Posted in Neuroblastomas, Potential Treatments, Research
3 Comments
Inflammatory breast cancer & ALK inhibitors
Below are two links to summaries of a study that suggests that women with inflammatory breast cancer are likely to have an ALK mutation and thus may benefit from taking an ALK inhibitor.
http://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=347
The relevant text for the second link starts about 15 or 20 paragraphs into the blog entry.
http://pharmastrategyblog.com/2011/11/update-from-aacr-molecular-targets-2011-1-breast-cancer.html/
Posted in Uncategorized
2 Comments
ALK Mutation studies
These studies present research on numerous mutations of the ALK gene, which can cause certain tumours to become resistant to particular drugs.
Articles about numerous potential ALK inhibitor drugs
These articles are overview or summary articles that discuss 3 of more potential drugs that may inhibit the growth of ALK + tumours.
Posted in Anaplastic Large-Cell Lymphomas, Potential Treatments, Research
Tagged ALK inhibitor, HSP90 inhibitor
4 Comments
FDA approval of Crizotinib (Xalkori) and background information
This page is for people to discuss and post links to research about the ALK inhibitor called Crizotinib also known as Xalkori (formerly PF-02341066).
Clinical trials & research on Heat Shock Protean 90 inhibitors
Notes about various Heat Shock Protean 90 (HSP90) inhibitors (which clinical studies have indicated inhibit ALK + cancers) including IPI-504 and STA9090.
HSP90 is a protean that appears to play a role in folding or stabalizing the EML4-ALK fusion gene. Thus inhibiting HSP90 indirectly inhibits ALK.
Clinical trial and research by Novartis
This page covers research by Novartis including the phase I study of the ALK inhibitor called LDK378. It also covers research on the ALK inhibitor TAE684. At this time it is not clear how the two relate, but presumably Novartis had a reason for moving forward with Human testing on LDK378 instead of TAE684.
Posted in Lung cancer, Potential Treatments, Research, Uncategorized
Tagged ALK inhibitor
10 Comments
Clinical trial by Astellas Pharma
This page is to track developments related to ASP-3026, which is an ALK inhibitor.
Posted in Uncategorized
4 Comments